IDEXX LABORATORIES INC /DE

Nasdaq: IDXX·Westbrook, Maine·

Price
$700.65
Base IV
$181.13

Valuation snapshot

Above bull case

At $700.65, the price is above even our bull case of $235.09.

Values per share, from an .

No growth
…
Loading earnings power
Base case
$181.13
26% of the price · range $135.31–$235.09
Price vs base case
287% above
$700.65 against $181.13
Base casevalued by DCF
Price vs base
Priceclose 11‑16

Whisker on the base case runs bear $135.31 to bull $235.09. Values per share.

Price against each value

Bear case
$135.31
Price 418% above
No growth
…
—
Base case
$181.13
Price 287% above
Researched byClaude Opus 5.5
Valuation Nov 13, 2026 · Price as of Nov 16, 2026How we got here

What does Idexx Laboratories Inc /de do?

IDEXX provides diagnostic instruments, laboratory services, and software to help veterinarians and researchers monitor the health of companion animals, livestock, and humans.

It brought in $4.7B of sales in the 12 months to Sep 2026.

IDEXX Catalyst One veterinary chemistry analyzerImage: Idexx Laboratories Inc /de
Industry
Healthcare
Based in
Westbrook, Maine
Trades on
Nasdaq as IDXX

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 25¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 37¢ of every dollar.

  • Making what it sells37¢
  • Research and development6¢
  • Sales, marketing and admin25¢
  • Interest and other costs1¢
  • Tax6¢
  • Left as profit25¢
Totals of the four quarters to Sep 2026, from the company's own filings. The split by product is from the latest fiscal year.

Who pays Idexx Laboratories Inc /de, and for what?

IDEXX sells diagnostic tests, instruments, laboratory services, and software for veterinarians, as well as tests for water, livestock, poultry, and dairy. It earns recurring revenue from consumables, tests, lab work, and subscriptions, alongside sales of instruments and other products.

Its customers include veterinary practices, water utilities, government and certified laboratories, livestock and dairy producers, processors, and human medical facilities.

  • Companion Animal Group

    91%

    Veterinary diagnostics, reference laboratory services, software, and imaging products.

    IDEXX Catalyst One veterinary chemistry analyzerImage: Idexx Laboratories Inc /de
  • Water quality products

    5%

    Tests and instruments used to detect and measure microbial contamination in water.

  • Livestock, Poultry and Dairy

    4%

    Diagnostic tests and services for animal health, herd management, and milk safety.

  • Other

    1%

    Human medical point-of-care diagnostic products and an out-licensing arrangement.

Share of the latest fiscal year's sales, as the company reports it.

Where its work physically happens, beyond headquarters:

  • Roswell manufacturing facility — Roswell, United States. The facility manufactures companion animal diagnostic products for IDEXX's largest segment, as well as human point-of-care products.
  • Scarborough Water and LPD facility — Scarborough, United States. This owned facility supports IDEXX's water testing and livestock, poultry and dairy product lines and its supply chain.
  • Memphis distribution center and reference lab — Memphis, United States. The site combines a major North American distribution operation with a veterinary reference laboratory, supporting product delivery and diagnostic services.
  • Hoofddorp international hub — Hoofddorp, Netherlands. Its international administrative offices, distribution center and warehouse support IDEXX's operations and product delivery outside the United States.
  • Newmarket Water manufacturing facility — Newmarket, United Kingdom. The facility manufactures products for IDEXX's Water segment, which reported $201.1 million in 2025 revenue.
See them on the globe

IDEXX Laboratories 2025 Form 10-K

How is the business doing?

Sales grew from $2.7B in 2020 to $4.3B in 2025, about 10% a year.

Running the business leaves about 32¢ of each sales dollar as operating profit, up from 26¢ in 2020.

After paying for its upkeep and new investment, it had $1.3B of cash to spare in the 12 months to Sep 2026.

Sales$4.3B
20162025
Operating margin32%
20162025
Free cash flow$1.1B
20162025
Each bar is one fiscal year (2016–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

IDEXX says it aims to create long-term value by improving the health and well-being of pets, people, and livestock.

“Enhancing the health and well-being of pets, people, and livestock.”

IDEXX Laboratories 2025 Form 10-K

What management says it is working on now:

  • Grow veterinary diagnostics

    Increase testing at existing veterinary customers, add customers, and expand use of existing and new tests.

    IDEXX Laboratories 2025 Form 10-K
  • Develop products and services

    Improve and introduce diagnostic tests, instruments, and software that help veterinary practices provide care and manage their work.

    IDEXX Laboratories 2025 Form 10-K
  • Improve laboratory and instrument operations

    Use automation, shared practices, purchasing scale, and better use of facilities to improve efficiency and costs.

    IDEXX Laboratories 2025 Form 10-K
  • Expand international water testing

    Broaden the water testing product range and seek regulatory approvals to support growth outside the United States.

    IDEXX Laboratories 2025 Form 10-K
  • Use AI responsibly

    Continue adding AI to products, services, and internal work while addressing accuracy, privacy, security, and regulatory concerns.

    IDEXX Laboratories 2025 Form 10-K

What's changing right now?

Growth is slowing. In Q3 2026 it sold 10% more than a year earlier. The year before, quarters averaged 13%.

Its operating margin is wider than a year ago: 33¢ per sales dollar, against 32¢.

Since Oct 2026 the share price has risen 22%, from $575.98 to $700.65.

Bull $235.09Base $181.13Bear $135.31Oct 30Nov 16 · $700.65
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start October 30, 2026.

Recently

Coming up

  • 2026

    Expand IDEXX Cancer Dx Panel

    IDEXX plans to add canine mast cell tumor detection to its Cancer Dx Panel in North America.

    IDEXX Laboratories 2025 Form 10-K
  • First half of 2026

    International launch of canine lymphoma test

    IDEXX expects to launch its Cancer Dx test for canine lymphoma internationally.

    IDEXX Laboratories 2025 Form 10-K
  • August 2026

    European Union AI rules take effect

    The company says the EU Artificial Intelligence Act will become fully effective, affecting products and services that use AI.

    IDEXX Laboratories 2025 Form 10-K

Our own estimate moved too: the base case went from $230.98 to $181.13 a share between our last two valuations.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Strong competition

    Competitors may bring products to market faster, offer lower prices, or have greater resources. Losing customers or failing to make products stand out could slow growth or reduce profitability.

    From the company's own filingsWould hit how fast sales growIDEXX Laboratories 2025 Form 10-K

  2. Reliance on suppliers

    Some important materials and products come from sole or single suppliers. A supply disruption or higher costs could limit product availability, reduce sales, or hurt margins.

    From the company's own filingsWould hit how fast sales growIDEXX Laboratories 2025 Form 10-K

  3. Regulatory approvals and changing rules

    Some products need government approval before sale or use in regulated testing. Delays, new requirements, or restrictions could raise costs or limit where products can be sold.

    From the company's own filingsWould hit how fast sales growIDEXX Laboratories 2025 Form 10-K

  4. Product development and AI

    New products may not launch on time or attract customers. Errors in AI systems or failure to meet privacy, security, or legal requirements could also damage trust and increase costs.

    From the company's own filingsWould hit how fast sales growIDEXX Laboratories 2025 Form 10-K

  5. Economic pressure on customers

    Cautious spending may reduce veterinary visits and testing, or delay clinics’ purchases of larger equipment and software systems. It may also affect water and livestock customers.

    From the company's own filingsWould hit how fast sales growIDEXX Laboratories 2025 Form 10-K

  6. Vet visit volumes are declining, so growth depends on price and on more tests per visit.

    From our researchWould hit how fast sales growFinviz: falling vet visits

  7. IDEXX keeps buying businesses, such as CoVet in 2026, which raises reinvestment above capex alone.

    From our researchWould hit how much it has to reinvestdvm360: IDEXX buys CoVet

Is it a good business?

From 2016 to 2025 it earned between 30% and 51% on the capital invested in it, a median of 45%. Its cost of capital in the latest valuation is 11.2%; returns were above it in every one of the 10 years.

From 2019 to 2025 it earned between 56% and 241% on its shareholders' equity, a median of 92%.

Over 10 years its operating margin ranged from 20¢ to 32¢ per sales dollar, a median of 26¢. Gross margin ran from 55¢ to 62¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on invested capital48%
20162025

Cost of capital 11.2%

Return on equity66%
20162025
Return on invested capital is operating profit after tax (at the median effective rate, 20%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

It bought back shares: the count fell 2.0% in a year, so each remaining share owns a slightly bigger slice.

It owes $651.3M more than it holds in cash, about 0.4 years of operating profit.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $700.65. Our put its value between $135.31 and $235.09, with $181.13 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $135.31

This scenario assumes IDEXX's recent near-10% sales growth fades toward the slower mid-single-digit pace it saw in weaker years like 2022 and 2024, and that its strong profitability slips a little as fewer pet visits and new investments weigh on results.

Base case, $181.13

This scenario assumes IDEXX keeps growing a bit below its recent near-10% pace, slowing gradually toward 6% a year, while its already high profitability edges up slightly as the business gets bigger.

Bull case, $235.09

This scenario assumes IDEXX keeps up the roughly 10% sales growth of the past year for longer, as vets use more of its tests and new analyzers, and that profits become a larger share of each dollar of sales.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects far more than we do.Price above value: 287%

For Idexx Laboratories Inc /de to be worth today's $700.65, sales would need to grow about 43.6% a year. We assume 7.4%. Over the last 5 years, sales grew 8.3% a year.

−10%0%+10%+20%+30%+40%+50%We assume 7.4%Past 5 yrs 8.3%Price needs 43.6%

Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.

Do you think sales can grow 43.6% a year?

Try your own numbers

We're moderately sure of this range: it scores 72 out of 100 on our checks. The weakest point is terminal-value dependency.

Test the assumptions

Our base value of $181.13 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average7.4%
  • Operating margin33.5%
  • Long-term growth rate3.0%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$181.13 -74.1%

Build